HRP20050245A2 - Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia - Google Patents
Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia Download PDFInfo
- Publication number
- HRP20050245A2 HRP20050245A2 HR20050245A HRP20050245A HRP20050245A2 HR P20050245 A2 HRP20050245 A2 HR P20050245A2 HR 20050245 A HR20050245 A HR 20050245A HR P20050245 A HRP20050245 A HR P20050245A HR P20050245 A2 HRP20050245 A2 HR P20050245A2
- Authority
- HR
- Croatia
- Prior art keywords
- epa
- use according
- acid
- treatment
- bulimia
- Prior art date
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims description 51
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims description 51
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims description 51
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims description 51
- 208000000103 Anorexia Nervosa Diseases 0.000 title claims description 33
- 206010006550 Bulimia nervosa Diseases 0.000 title claims description 9
- 208000032841 Bulimia Diseases 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 19
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 16
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 235000021342 arachidonic acid Nutrition 0.000 claims description 8
- 229940114079 arachidonic acid Drugs 0.000 claims description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 7
- 235000020778 linoleic acid Nutrition 0.000 claims description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 208000035850 clinical syndrome Diseases 0.000 claims description 4
- 125000004494 ethyl ester group Chemical group 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 31
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 31
- 229960002600 icosapent ethyl Drugs 0.000 description 26
- 235000013305 food Nutrition 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000009231 family therapy Methods 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000004630 mental health Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000005686 eating Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000006996 mental state Effects 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 238000001671 psychotherapy Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000030814 Eating disease Diseases 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 241000594592 Lanugo Species 0.000 description 2
- 206010027940 Mood altered Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000020805 dietary restrictions Nutrition 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 208000012866 low blood pressure Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000020802 micronutrient deficiency Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036301 sexual development Effects 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101150031621 CGAS gene Proteins 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019138 food restriction Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000013403 specialized food Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0221480.7A GB0221480D0 (en) | 2002-09-16 | 2002-09-16 | Treatment of anorexia nervosa (AN) and bulimia |
| PCT/GB2003/003985 WO2004024136A1 (fr) | 2002-09-16 | 2003-09-16 | Utilisation de l'acide eicosapentanoique (epa) pour traiter l'anorexie nerveuse et la boulimie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050245A2 true HRP20050245A2 (en) | 2005-10-31 |
Family
ID=9944164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050245A HRP20050245A2 (en) | 2002-09-16 | 2005-03-16 | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060135608A1 (fr) |
| EP (1) | EP1556028A1 (fr) |
| JP (1) | JP2006503031A (fr) |
| KR (1) | KR20050042823A (fr) |
| CN (1) | CN1694694A (fr) |
| AU (1) | AU2003269138A1 (fr) |
| BR (1) | BR0317857A (fr) |
| CA (1) | CA2499142A1 (fr) |
| GB (1) | GB0221480D0 (fr) |
| HR (1) | HRP20050245A2 (fr) |
| IS (1) | IS7744A (fr) |
| MX (1) | MXPA05002943A (fr) |
| NO (1) | NO20051847L (fr) |
| NZ (1) | NZ538793A (fr) |
| PL (1) | PL375726A1 (fr) |
| RS (1) | RS20050226A (fr) |
| RU (1) | RU2330653C2 (fr) |
| TW (1) | TW200410682A (fr) |
| WO (1) | WO2004024136A1 (fr) |
| ZA (1) | ZA200502161B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| CA2545190A1 (fr) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | Agent preventif/therapeutique pour traiter les troubles de la parole |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| KR101430214B1 (ko) | 2006-12-28 | 2014-08-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| ES2561482T3 (es) | 2007-02-15 | 2016-02-26 | Centre De Recherche Sur Les Biotechnologies Marine | Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos |
| CA2677670C (fr) | 2007-03-20 | 2010-08-03 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprenant des monoglycerides d'acides gras polyinsatures ou des derives de ceux-ci et leurs utilisations |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| LT3318255T (lt) * | 2009-06-15 | 2021-05-25 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija |
| AU2012214260A1 (en) * | 2011-02-11 | 2013-07-25 | E. I. Du Pont De Nemours And Company | An eicosapentaenoic acid concentrate |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
| WO2019153073A1 (fr) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Monoglycérides d'acides gras polyinsaturés, compositions, procédés et utilisations correspondants |
| US20210130897A1 (en) * | 2018-04-16 | 2021-05-06 | Quadrant Biosciences Inc. | Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status |
| CN112384212A (zh) | 2018-05-03 | 2021-02-19 | Scf制药股份有限公司 | 多不饱和脂肪酸单甘油酯、其组合物、方法和用途 |
| CN109276262B (zh) * | 2018-07-30 | 2021-01-26 | 中国科学院心理研究所 | 一种用于筛选高危进食障碍的检测系统 |
| US20210299065A1 (en) * | 2020-03-27 | 2021-09-30 | Homeostasis Therapeutics, Limited | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
-
2003
- 2003-09-16 CA CA002499142A patent/CA2499142A1/fr not_active Abandoned
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 EP EP03750919A patent/EP1556028A1/fr not_active Ceased
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/fr active Application Filing
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Application Discontinuation
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
-
2005
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006503031A (ja) | 2006-01-26 |
| EP1556028A1 (fr) | 2005-07-27 |
| US20060135608A1 (en) | 2006-06-22 |
| TW200410682A (en) | 2004-07-01 |
| MXPA05002943A (es) | 2005-06-03 |
| AU2003269138A1 (en) | 2004-04-30 |
| GB0221480D0 (en) | 2002-10-23 |
| NO20051847L (no) | 2005-04-15 |
| CA2499142A1 (fr) | 2004-03-25 |
| CN1694694A (zh) | 2005-11-09 |
| KR20050042823A (ko) | 2005-05-10 |
| IS7744A (is) | 2005-03-15 |
| RU2005107416A (ru) | 2006-01-20 |
| RU2330653C2 (ru) | 2008-08-10 |
| WO2004024136A1 (fr) | 2004-03-25 |
| NZ538793A (en) | 2007-05-31 |
| RS20050226A (en) | 2007-09-21 |
| BR0317857A (pt) | 2005-12-06 |
| PL375726A1 (en) | 2005-12-12 |
| ZA200502161B (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050245A2 (en) | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia | |
| Canani et al. | Short-and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease | |
| CN110114067A (zh) | 3-羟基丁酸甘油酯用于创伤性脑损伤 | |
| Drabińska et al. | Recent advances in the application of a ketogenic diet for obesity management | |
| CN110167637A (zh) | 3-羟基丁酸甘油酯用于偏头痛症状管理 | |
| EP2124977A1 (fr) | Procédé de traitement ou de prévention d'une inflammation généralisée | |
| EP2214683A2 (fr) | Dosage unitaire pour la santé cérébrale | |
| JP2023100870A (ja) | 対象におけるマイトファジーを改善するための方法 | |
| Collins et al. | The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants< 29 weeks’ gestation | |
| US6753350B1 (en) | Method to reduce the incidence of intraventricular hemorrhage in preterm infants | |
| WO2017176199A1 (fr) | Composition de macronutriments à utiliser dans un procédé pour le traitement du diabète gestationnel | |
| JP6368368B2 (ja) | ｐ−アニスアルデヒドを使用する組成物及び方法 | |
| WO2022210856A1 (fr) | Composition pour améliorer la qualité du sommeil | |
| WO2022244727A1 (fr) | Composition destinée à améliorer la fonction cognitive | |
| Noland | Lipidomics: Clinical Application | |
| US6482434B1 (en) | Method for reducing adverse effects of a weight loss regimen | |
| Rahardjo et al. | Formulating Diet for Transitional Feeding in Tuberculous Meningitis Patient during Hospital Care and through to Period of Home Healthcare | |
| JP6281919B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| Pelekhaty et al. | Nutritional Management of the Trauma Patient | |
| JP2023525712A (ja) | 認知機能を改善するためのｍｃｔ製剤 | |
| RU2338543C2 (ru) | Способ комплексного лечения терапевтически резистентных реактивных депрессий | |
| Miller | The effects of docosahexaenoic acid intake during pregnancy and lactation on infant growth and neurocognitive development and the associated effects of genetic variants of the FADS1 FADS2 gene cluster | |
| US20180085382A1 (en) | Compositions and methods for cognitive health and memory | |
| Migliozzi | The nervous system and | |
| Tolbert | Enhancing weight gain in long-term care residents at risk for weight loss through protein and calorie fortification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080916 Year of fee payment: 6 |
|
| OBST | Application withdrawn |